Opko Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $587.9M-17.6% YoYTTM through 30 Jun 2026
Net Income -$72.9MTTM through 30 Jun 2026
Free Cash Flow -$134MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 33.9% |
| EBITDA Margin | 7.1% |
| Operating Margin | -19.3% |
| Net Margin | -12.4% |
Returns
-17.8%ROE
-11.7%ROA
Balance Sheet Health
Debt / Equity0.27x
Current Ratio3.97x
Net Debt-$37.7Mnet cash position
Cash & Equivalents$300.8M
Quality Metrics
Altman Z-Score-0.14
Piotroski F-Score2 / 9
FCF Margin-22.8%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $606.9M
Diluted EPS-$0.09TTMFY2025: $-0.30
Dividend
No dividend
Capital Allocation
R&D Spend$125.2M
Capex Intensity1.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Diagnostics | $370.3M | -23.0% | View detailsRestructuring and focusing on core clinical testing services in NY/NJ and the 4Kscore franchise. |
| Pharmaceuticals | $236.6M | +1.8% | View detailsAdvancing clinical pipeline with ModeX multispecific antibody platform and Regeneron collaboration. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.